Participant flow

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome · Source last updated 2013-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Mifepristone was administered at doses of 300-1200 mg daily.

   id

   FG000

   title

   Mifepristone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Subject was too ill to travel.

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Subject was non-compliant.

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         50

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         34

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         16

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Adults with endogenous Cushing's Syndrome associated with either type 2 diabetes mellitus/impaired glucose tolerance or a diagnosis of hypertension.

recruitment Details

24 week multicenter, open-label trial after failed multimodality therapy at 14 U.S. academic medical centers and three private research centers.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice